ArticleCureus2025
Severe Reversible Heart Failure Enhanced by Sorafenib Treatment for Hepatocellular Carcinoma.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The multitarget oral tyrosine kinase inhibitor sorafenib is an effective first-line treatment option in unresectable hepatocellular carcinoma. Through its mechanism of action, it has been associated with cardiotoxicity, mainly hypertension, which is usually low-grade and well-managed with behavioral changes and antihypertensor treatment adjustment, if needed. Acute, symptomatic heart failure is rarely described. We present the case of a patient with priors of arterial hypertension, dyslipidemia, type 2 diabetes mellitus, and non-alcoholic steatohepatitis-related cirrhosis of the liver, with the diagnosis of hepatocellular carcinoma treated with sorafenib, with previous excellent tolerability and stable disease. Dyspnea and detection of atrial fibrillation with severe reduction of left ventricular ejection fraction (26%), three years after the beginning of treatment, led to the diagnosis of acute heart failure with reduced ejection fraction and class IV New York Heart Association symptoms, confirmed to be enhanced by sorafenib, and partially reversible after its suspension and optimization of cardiological treatment. A multidisciplinary approach, prompt recognition, and aggressive treatment of this rare and severe toxicity are essential in determining a favorable outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.